Blue­bird bio adds a key process to pi­o­neer­ing gene ther­a­py as it ramps up a piv­otal PhI­II

Blue­bird bio be­lieves it has de­vel­oped a new process that will make a marked im­prove­ment in their pi­o­neer­ing gene ther­a­py pro­grams, promis­ing to de­liv­er a sig­nif­i­cant im­pact on pa­tient out­comes in a new­ly-launched piv­otal study for Lenti­Glo­bin.

Late last year, blue­bird bio ex­ecs were forced to ex­plain why the lat­est da­ta on Lenti­Glo­bin had proved dis­ap­point­ing in a small set of sick­le cell pa­tients be­ing test­ed. In­stead of the cure that blue­bird $BLUE was look­ing for, sev­er­al pa­tients ex­pe­ri­enced a less than op­ti­mal re­sponse in pro­duc­ing an­ti-sick­ling he­mo­glo­bin, which caused more than a few in­vestors in the com­pa­ny to do a dou­ble take on the com­pa­ny’s prospects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.